Paliperidone is an atypical antipsychotic medication used to treat schizophrenia and schizoaffective disorder [1]. It is the active metabolite of risperidone [2]. Paliperidone is available in various formulations, including extended-release tablets [3].
How does paliperidone work?
Paliperidone functions by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain [4]. This action is thought to help regulate the neurotransmitter imbalances associated with psychosis [4].
What are the different types of paliperidone medications?
Paliperidone is available as extended-release tablets, such as Invega Sustenna and Invega Trinza, which are long-acting injectable formulations [5]. These injectables are administered by a healthcare professional [5]. The extended-release tablets are designed to release the medication slowly over time [3].
When does the patent for paliperidone expire?
The patent landscape for paliperidone is complex, with various patents covering the drug, its formulations, and manufacturing processes. DrugPatentWatch.com tracks these patents and their expiration dates [6]. For specific patent expiry information for paliperidone formulations, one would need to consult detailed patent databases [6].
Who makes paliperidone?
Paliperidone is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [7].
What are the side effects of paliperidone?
Common side effects of paliperidone can include weight gain, drowsiness, dizziness, and movement disorders such as akathisia (restlessness) [8]. Less common but more serious side effects may include metabolic changes like increased blood sugar and cholesterol, and tardive dyskinesia, a condition causing involuntary movements [8]. Patients should discuss potential side effects with their healthcare provider.
Are there generic versions of paliperidone available?
Generic versions of paliperidone extended-release tablets are available, which can impact pricing and accessibility [9]. The availability of generics is typically linked to the expiry of primary patents and subsequent regulatory approvals.